Publications by authors named "Pramod G Nagaraju"

Background: Mitochondrial dysfunction is one of the major hallmarks of Parkinson's disease (PD). Recently, angiotensin II type 1 and type 2 receptors (AT1R, AT2R) were reported to be present on the mitochondrial membrane. Both are crucial players in the brain renin-angiotensin system (RAS).

View Article and Find Full Text PDF
Article Synopsis
  • The study evaluated the safety, toxicity, and distribution of eugenol nanoparticles (EONs) in Wistar rats after oral administration, observing no adverse effects or inflammation.
  • Biodistribution analysis showed that eugenol was rapidly absorbed with a peak concentration (Cmax) of 15.05 μg/mL in blood plasma at around 8 hours (Tmax).
  • EONs were found to enhance the stability and solubility of eugenol while showing a promising safety profile, suggesting potential for continued research and application.
View Article and Find Full Text PDF

Alzheimer's disease (AD) is a cumulative form of dementia associated with memory loss, cognition impairment, and finally leading to death. AD is characterized by abnormal deposits of extracellular beta-amyloid and intracellular Tau-protein tangles throughout the brain. During pathological conditions of AD, Tau protein undergoes various modifications and aggregates over time.

View Article and Find Full Text PDF

The aggregation of tau protein is one of the hallmarks for Alzheimer's disease, resulting in neurodegeneration. The peptidomimetics strategy to prevent tau aggregation is more specific over other small molecules. In the present study, we analyzed the effect of amyloid-β-derived peptidomimetics for inhibiting heparin-induced tau aggregation .

View Article and Find Full Text PDF

The influence of protein (sodium caseinate-SC), polysaccharide (maltodextrin-MD; pectin-PC) and their Maillard conjugates (sodium caseinate maltodextrin conjugate-SCMDC; sodium caseinate pectin conjugate-SCPCC) were studied on the physico-chemical and biological properties of eugenol nanoemulsions/powder. The chemical composition was optimized using Taguchi design. The particles size of eugenol nanoemulsions with SC, MD, PC, SCMDC and SCPCC were 104.

View Article and Find Full Text PDF

Tau is an axonal protein known to form abnormal aggregates and is the biomarker of Alzheimer's disease. Metal-based therapeutics for inhibition of Tau aggregation is limited and rarely reported in contemporary science. Here, we report the first example of rationally designed molecular cobalt(II)-complexes for effective inhibition of Tau and disaggregation of preformed Tau fibrils.

View Article and Find Full Text PDF